SEC Form 4 · accession 0001140361-18-026604
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqueline Studer
Officer — CVP, Gen. Counsel & Secretary
Period of report
May 30, 2018
Accepted (ET)
May 31, 2018 · 5:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 30, 2018 | M | 1,185 | $79.54 | A | 6,300 | D | |
| Common StockF2 | May 30, 2018 | S | 475 | $209.9804 | D | 5,825 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right-to-buy)F4,F3 | $79.54 | May 30, 2018 | M | 1,185 | D | — | Feb 13, 2025 | Common Stock | 1,185 | 4,295 | D |
Explanation of responses
- F1Includes 38 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 30, 2018.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $209.97 to a high of $209.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F4Not applicable.